$XAGE Cashflow Statement | Understand Stock

$XAGE

$2.32 +$0.00 (0.0%) Close

$XAGE Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statement of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 11 months to Dec 31, 2021
Cash flows from operating activities:
Net loss from continuing operations
Loss from discontinued operations, net of tax
Gain on sale of discontinued operations
Adjustments to reconcile net loss to net cash used in operating activities:
Interest earned in Trust Account
Change in fair value of overallotment liability
Gain on sale of discontinued operations
Stock-based compensation
Depreciation and amortization of intangible assets
Amortization of right of use assets
Change in fair value of earnout liabilities
Inventory write-down
Amortization of debt discount
Change in fair value of forward purchase agreement
Loss on forward purchase agreement
Change in fair value of derivative liabilities
Non-cash interest expense
Loss on extinguishment of debt
Interest recognized upon default
Shares issued for interest

Changes in operating assets and liabilities:
Accounts receivable and other current assets
Other current assets
Inventory
Prepaid expenses
Accrued expenses
Due to related party
Income taxes receivable
Assets available for sale
Accounts payable
Accrued expenses and other liabilities
Lease liability
Accrued interest - related and third-party
Liabilities available for sales
Accrued interest
Income tax payable
Liabilities available for sale

Net cash used in operating activities
Cash flows from investing activities
Investment of cash into Trust Account
Cash paid for Elevai Acquisition transaction costs
Purchases of property and equipment
Cash paid in AxoBio Disposition
Net cash used in investing activities

Cash flows from financing activities:
Proceeds from related party
Payment to related party
Proceeds from issuance of Public Units
Proceeds from issuance of Private Units
Proceeds from issuance of Common Stock, net of costs
Proceeds from issuance of loans
Proceeds from exercise of Common Stock warrants
Repayment of loans
Deferred offering costs
Proceeds from warrant exercise
Gross proceeds from Business Combination
Transaction costs paid in connection with the Business Combination
Cash transferred in connection with Forward Purchase Agreement
Proceeds from common stock option exercises
Payment of convertible notes
Proceeds from convertible notes
Issuance of Series C-1 preferred stock
Repurchase of common stock
Payment of debt financing fee
Net cash provided by financing activities

Net Change in Cash
Cash - January 21, 2021 (inception)
Cash - end of the period
Deferred underwriting fee payable
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents - beginning of period
Cash and cash equivalents - end of period
Offering costs paid by Sponsor in exchange for issuance of Class B common stock
Capital contribution by the Sponsor through transfer of Class B shares
Offering costs included in accrued offerings costs
Deferred underwriting commissions
Accretion of the interest earned in Trust Account
Supplemental cash flow information:
Interest paid
Income taxes refunded
Non-cash financing activity:
Accrued Series A preferred stock dividends
Accrued Series C-1 preferred stock dividends
Accrued Series C-2 preferred stock dividends
Conversion of convertible notes and accrued notes to Series C-2 preferred stock
Warrants issued in connection with convertible notes
Warrants issued in connection with Series C-1 preferred stock
Initial recognition of derivative liabilities
Fair value of shares issued in Elevai Acquisition
Consideration payable
Earnout liabilities in Elevai Acquisition
Insurance premium financing agreements
Fair value of shares received in AxoBio Disposition
Net assets sold in AxoBio Disposition
Common Stock issued in connection with conversion of Notes
Decrease in right of use asset and lease liabilities related to termination of lease
Net assets acquired in AxoBio Acquisition
Earnout liability and deferred consideration payable in connection with AxoBio Acquisition
Issuance of Series A preferred stock and common stock in connection with AxoBio Acquisition
Total net assets acquired in AxoBio Acquisition
Accrued Legacy Series A preferred stock dividends
Accrued Legacy Series C-1 preferred stock dividends
Accrued Legacy Series C-2 preferred stock dividends
Debt discount recorded in connection with loans payable
Conversion of common stock and preferred stock in connection with the Business Combination

Comments